Plain-English translation of NCT05438043 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a long-term extension study for people with multiple myeloma (a type of blood cancer) who have already been participating in earlier clinical trials using . The study gives you the chance to keep receiving this medication after your original trial ends, as long as it's helping you and you haven't experienced serious side effects. Doctors will continue to monitor your health and safety throughout your participation.
Once a clinical trial ends, patients who are benefiting from the medication may no longer have access to it. This study solves that problem by allowing continued treatment for people who need it, while also gathering important long-term safety information that helps doctors understand how well the medication works over extended periods.
You will continue to receive on a regular schedule (either as an injection under the skin or through an IV infusion, depending on what you received before) on Day 1 of each 28-day cycle. You may receive it alone or combined with other standard cancer medications, just as you were in your previous trial. Throughout the study, you'll have regular visits with your doctor to check how you're doing, monitor for any side effects, and confirm the treatment is still working well for you.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
United States